ArticleBMJ open diabetes research & care2026
EPCs-derived exosomal miR-7116-3p alleviate high glucose-induced endothelial cell dysfunction by targeting Orai1-IGFBP3 complexes.
Article in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic vascular complications are predominantly caused by high glucose (HG)-induced endothelial dysfunction. Exosomes derived from endothelial progenitor cells (EPCs-EXOs) have shown therapeutic potential by modulating cellular functions through the delivery of bioactive cargos, particularly microRNAs (miRNAs). This study examines the role of EPCs-EXOs and their miRNA cargo in mitigating HG-induced endothelial dysfunction by targeting the Orai1-insulin-like growth factor-binding protein 3 (IGFBP3) signaling axis, a critical mediator of store-operated calcium entry (SOCE) and vascular pathology in diabetes. RESEARCH DESIGN AND
methodsHuman coronary artery endothelial cells (HCAECs) were cultured under HG (25 mM) or normal glucose (5.6 mM) conditions to model endothelial dysfunction. Cellular proliferation, apoptosis, and migration were evaluated through functional assays. EPCs-EXOs were isolated from mouse bone marrow-derived EPCs and characterized via nanoparticle tracking analysis, transmission electron microscopy. A type 2 diabetic mouse model was established using streptozotocin, and atherosclerotic plaque formation was quantified by Oil Red O staining. miRNA profiling identified miR-7116-3p as a potential regulator. HCAECs and mice with diabetes were treated with EPCs-EXOs, and miR-7116-3p mimics or inhibitors were employed to evaluate the specific effects on Orai1 and IGFBP3 expression and endothelial function.
resultsEPCs-EXOs significantly attenuated HG-induced abnormalities in HCAECs proliferation, apoptosis, and migration, and reduced atherosclerotic plaque formation in mice with diabetes. HG conditions upregulated Orai1 and IGFBP3 expression and promoted SOCE activity, whereas EPCs-EXOs suppressed these responses. Overexpression of Orai1 or IGFBP3 abolished the protective effects of EPCs-EXOs, underscoring their essential role. miRNA profiling identified miR-7116-3p within EPCs-EXOs as a key regulator that directly targets Orai1 and IGFBP3 messenger RNAs.
conclusionEPCs-EXOs alleviate HG-induced endothelial dysfunction by suppressing the Orai1-IGFBP3 signaling axis, with miR-7116-3p acting as a pivotal regulator of these targets. These findings reveal a novel mechanism and support the therapeutic potential of miR-7116-3p-enriched EPCs-EXOs for the treatment of diabetic cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.